Filtros de búsqueda

Lista de obras de Alfredo Falcone

5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.

artículo científico publicado en 2001

5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.

artículo científico publicado en 2004

5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.

artículo científico publicado en 2008

A Model of a Zebrafish Avatar for Co-Clinical Trials

scientific article published on 13 March 2020

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

artículo científico publicado en 2015

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

artículo científico publicado en 2008

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

artículo científico publicado en 2008

A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity

artículo científico publicado en 2006

A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

artículo científico publicado en 2004

A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients

artículo científico publicado en 2012

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

artículo científico publicado en 2017

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

artículo científico publicado en 2004

A still missing piece of the FIRE-3 puzzle.

artículo científico publicado en 2016

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

artículo científico publicado en 2019

AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer

scientific article published on 04 May 2019

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

artículo científico publicado en 2018

Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience.

artículo científico publicado en 2017

Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).

artículo científico publicado en 2003

Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms

artículo científico publicado en 2013

Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.

artículo científico publicado en 2005

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

artículo científico publicado en 2005

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases

artículo científico publicado en 2013

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.

artículo científico publicado en 2018

An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer

artículo científico publicado en 2016

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

artículo científico publicado en 2011

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

artículo científico

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

artículo científico publicado en 2016

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward.

artículo científico publicado en 2016

Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

artículo científico publicado en 2010

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

artículo científico publicado en 2019

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

artículo científico publicado en 2017

BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases

scientific article published on 01 December 2018

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

artículo científico publicado en 2015

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

artículo científico publicado en 2015

Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

scientific article published on 08 March 2019

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial

artículo científico publicado en 2019

Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.

artículo científico publicado en 2014

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

artículo científico publicado en 2010

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

artículo científico publicado en 2009

Biomarkers and response to bevacizumab--letter

scientific article published on 01 February 2014

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

artículo científico publicado en 2002

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

artículo científico publicado en 2015

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients

scientific article published on 11 July 2019

Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.

artículo científico publicado en 2013

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.

artículo científico publicado en 2016

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

artículo científico publicado en 2008

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

artículo científico publicado en 2010

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

artículo científico publicado en 2017

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics

artículo científico publicado en 2019

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

artículo científico publicado en 2010

Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.

artículo científico publicado en 2002

Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

artículo científico publicado en 2009

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

artículo científico publicado en 2010

Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

artículo científico publicado en 2012

Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study

artículo científico publicado en 2009

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database ⬇️

artículo científico publicado en 2017

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

artículo científico publicado en 2016

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

artículo científico publicado en 2009

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2011

Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients

scientific article published on 06 November 2019

Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer

scientific article published on 08 December 2020

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

artículo científico publicado en 2016

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

artículo científico publicado en 2012

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

artículo científico publicado en 2015

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD da ⬇️

artículo científico publicado en 2018

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.

artículo científico publicado en 2016

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

artículo científico publicado en 2018

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

artículo científico publicado en 2008

Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment

artículo científico publicado en 2010

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

artículo científico publicado en 2016

Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).

artículo científico publicado en 2012

Current status and perspectives in immunotherapy for metastatic melanoma.

artículo científico publicado en 2018

Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

artículo científico publicado en 2005

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

artículo científico publicado en 2011

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

artículo científico publicado en 2017

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Dedicated supportive care team at the oncology unit: a model of simultaneous care for cancer patients

artículo científico publicado en 2014

Dedifferentiated liposarcoma: when eribulin can make the difference

artículo científico publicado en 2019

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

artículo científico publicado en 2012

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

artículo científico publicado en 2018

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

artículo científico publicado en 2010

Discordant somatic and germlineVEGF-Agenotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

artículo científico publicado en 2009

Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy

artículo científico publicado en 2014

Do we need biopsies of metastases for colorectal cancer patients?

artículo científico publicado en 2009

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

artículo científico publicado en 2014

Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients

scientific article published on 01 June 1994

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

artículo científico publicado en 2017

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2013

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

artículo científico publicado en 2016

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

artículo científico publicado en 2012

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

artículo científico publicado en 2017

Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib

scientific article published on 28 January 2019

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

artículo científico publicado en 2015

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

artículo científico publicado en 2016

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

artículo científico publicado en 2009

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

artículo científico publicado en 2011

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

artículo científico publicado en 2019

Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker

artículo científico publicado en 1989

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

artículo científico publicado en 2016

FOLFOXIRI and bevacizumab for metastatic colorectal cancer

artículo científico publicado en 2015

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

artículo científico publicado en 2013

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

artículo científico publicado en 2016

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

artículo científico publicado en 2013

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

artículo científico publicado en 2015

Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?

artículo científico publicado en 2011

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

artículo científico publicado en 2008

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer

artículo científico publicado en 2006

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

artículo científico

First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.

artículo científico publicado en 2017

First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.

artículo científico publicado en 2016

First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design

scientific article published on 09 January 2020

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

artículo científico publicado en 2018

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

artículo científico publicado en 2014

Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.

artículo científico

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

artículo científico publicado en 2010

Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.

artículo científico publicado en 2016

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

artículo científico publicado en 2019

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice

artículo científico publicado en 2010

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

artículo científico publicado en 2008

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease

artículo científico publicado en 2012

High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer

artículo científico publicado en 2012

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

artículo científico publicado en 2013

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.

artículo científico publicado en 2010

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

artículo científico publicado en 2011

Hypersensitivity reactions related to oxaliplatin (OHP).

artículo científico publicado en 2003

Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?

scientific article published on 28 February 2020

Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care

artículo científico publicado en 2016

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

artículo científico publicado en 2019

Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.

artículo científico publicado en 2010

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

artículo científico publicado en 2017

Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3

artículo científico publicado en 2019

Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients

article

Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling

artículo científico publicado en 2005

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).

artículo científico publicado en 2004

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d

artículo científico publicado en 2015

Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery

scientific article published on 01 October 1999

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

artículo científico publicado en 2014

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2010

Integrated safety summary for trifluridine/tipiracil (TAS-102).

artículo científico publicado en 2017

Interprofessional spiritual care in oncology: a literature review

artículo científico publicado en 2019

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

artículo científico publicado en 2006

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

scientific article published on 04 February 2019

KRAS and BRAF genotyping of synchronous colorectal carcinomas

artículo científico publicado en 2014

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

artículo científico publicado en 2009

KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting

artículo científico publicado en 2014

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

artículo científico publicado en 2019

Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer

artículo científico publicado en 2002

Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.

artículo científico publicado en 2011

Liver transplantation for metastatic sinonasal undifferentiated carcinoma: a case report

artículo científico publicado en 2008

Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions

artículo científico publicado en 2018

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

artículo científico publicado en 2016

MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy

artículo científico publicado en 2015

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

artículo científico publicado en 2010

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

scientific article published on 03 July 2019

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.

artículo científico publicado en 2017

Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.

artículo científico publicado en 2009

Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?

artículo científico publicado en 2010

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

artículo científico publicado en 2010

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

artículo científico publicado en 2010

Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

artículo científico

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer

artículo científico publicado en 2015

Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis.

artículo científico publicado en 2017

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

artículo científico publicado en 2014

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

artículo científico publicado en 2015

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

artículo científico publicado en 2012

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

artículo científico publicado en 2017

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

scientific article published on 01 January 2020

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

scientific article published on 01 September 2018

Not only chemotherapy in the second-line treatment of metastatic gastric cancer

artículo científico publicado en 2014

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

article

Optimal approach to potentially resectable liver metastases from colorectal cancer

artículo científico publicado en 2008

Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation

Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study

scientific article published on 01 September 2000

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

artículo científico publicado en 2011

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

artículo científico publicado en 2019

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

artículo científico publicado en 2018

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

artículo científico publicado en 2012

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

artículo científico publicado en 2009

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

artículo científico publicado en 2017

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

artículo científico publicado en 2011

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

artículo científico publicado en 2014

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

artículo científico publicado en 2008

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

scientific article published on 01 April 2007

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.

artículo científico publicado en 2014

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

artículo científico publicado en 2018

Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine.

artículo científico publicado en 1998

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction

artículo científico publicado en 2008

Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells

scientific article published on 01 June 2019

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial

artículo científico publicado en 2019

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

artículo científico publicado en 2009

Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer

scientific article published on 01 December 1996

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

artículo científico publicado en 2010

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

artículo científico publicado en 2015

Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma

artículo científico publicado en 1994

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

artículo científico publicado en 2007

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

artículo científico publicado en 2015

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients

scientific article published on 13 October 2020

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer

scientific article published on 21 June 2018

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

artículo científico publicado en 2010

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

artículo científico publicado en 2015

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.

artículo científico publicado en 2011

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database ⬇️

artículo científico publicado en 2016

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy

scientific article published on 13 September 2018

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

artículo científico publicado en 2018

Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib

artículo científico publicado en 2020

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

artículo científico publicado en 2018

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management

artículo científico publicado en 2015

Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation

artículo científico publicado en 2017

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

artículo científico publicado en 2015

Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter

scientific article published on 18 July 2012

Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database

artículo científico publicado en 2018

Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion

artículo científico publicado en 2005

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

artículo científico publicado en 2014

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

artículo científico publicado en 2013

Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study

artículo científico publicado en 1999

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

artículo científico publicado en 2017

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

artículo científico publicado en 2018

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

artículo científico publicado en 2016

Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.

artículo científico publicado en 2014

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

artículo científico publicado en 2015

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

artículo científico publicado en 2010

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

artículo científico

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

scientific article published on 01 March 2019

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

artículo científico publicado en 2009

Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer

artículo científico publicado en 1988

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

scientific article published on 06 September 2018

Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer

artículo científico publicado en 2017

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Re

artículo científico publicado en 2017

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

artículo científico publicado en 2013

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

artículo científico publicado en 2010

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

artículo científico publicado en 2011

Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience

scientific article published on 18 February 2019

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

artículo científico publicado en 2014

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

artículo científico publicado en 2019

Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients

artículo científico publicado en 2016

Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All ⬇️

artículo científico publicado el 1 de septiembre de 2010

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

artículo científico publicado en 2015

Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.

artículo científico publicado en 2006

Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature

artículo científico publicado en 2016

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

artículo científico publicado en 2017

Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.

artículo científico publicado en 2002

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

artículo científico publicado en 2011

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

artículo científico publicado en 2017

Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen

artículo científico publicado en 2015

Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer

artículo científico publicado en 2017

Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.

artículo científico publicado en 1998

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

artículo científico publicado en 2016

Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.

artículo científico publicado en 1994

TAS-102 for the treatment of metastatic colorectal cancer.

artículo científico publicado en 2015

TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply

artículo científico publicado en 2015

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

artículo científico publicado en 2017

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer

artículo científico publicado en 2018

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

artículo científico publicado en 2017

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

artículo científico publicado en 2018

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

artículo científico publicado en 2016

The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

scholarly article by Carlotta Antoniotti published in August 2018

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer

artículo científico publicado en 2018

The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms

artículo científico publicado en 2012

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.

artículo científico

Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients

artículo científico publicado en 2016

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.

artículo científico publicado en 2016

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial

scientific article published on 07 February 2019

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

artículo científico publicado en 2016

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

scientific article published on 08 May 2018

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

artículo científico publicado en 2008

VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.

artículo científico publicado en 2008

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

artículo científico publicado en 2013

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

scientific article published on 04 September 2019

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer

scientific article published on 12 February 2019

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

artículo científico publicado en 2015

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

scientific article published on 23 December 2008

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

scientific article published on 01 May 2007

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda